SK287869B6 - Beta-carboline pharmaceutical compositions - Google Patents

Beta-carboline pharmaceutical compositions Download PDF

Info

Publication number
SK287869B6
SK287869B6 SK173-2002A SK1732002A SK287869B6 SK 287869 B6 SK287869 B6 SK 287869B6 SK 1732002 A SK1732002 A SK 1732002A SK 287869 B6 SK287869 B6 SK 287869B6
Authority
SK
Slovakia
Prior art keywords
formulation
amount
active compound
weight
present
Prior art date
Application number
SK173-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK1732002A3 (en
Inventor
Peter L. Oren
Neil R. Anderson
Martha A. Kral
Original Assignee
Icos Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22519593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287869(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corporation filed Critical Icos Corporation
Publication of SK1732002A3 publication Critical patent/SK1732002A3/sk
Publication of SK287869B6 publication Critical patent/SK287869B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SK173-2002A 1999-08-03 2000-04-26 Beta-carboline pharmaceutical compositions SK287869B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14692499P 1999-08-03 1999-08-03
PCT/US2000/011130 WO2001008686A1 (en) 1999-08-03 2000-04-26 Beta-carboline pharmaceutical compositions

Publications (2)

Publication Number Publication Date
SK1732002A3 SK1732002A3 (en) 2002-05-09
SK287869B6 true SK287869B6 (sk) 2012-02-03

Family

ID=22519593

Family Applications (1)

Application Number Title Priority Date Filing Date
SK173-2002A SK287869B6 (sk) 1999-08-03 2000-04-26 Beta-carboline pharmaceutical compositions

Country Status (29)

Country Link
US (2) US7182958B1 (es)
EP (3) EP1200091B1 (es)
JP (2) JP2003505509A (es)
KR (2) KR20060093355A (es)
CN (1) CN1213754C (es)
AT (1) ATE399554T1 (es)
AU (2) AU4491200A (es)
BR (1) BR0012863A (es)
CA (1) CA2379948C (es)
CZ (1) CZ304624B6 (es)
DE (1) DE60039357D1 (es)
DK (1) DK1200090T3 (es)
DZ (1) DZ3179A1 (es)
EA (1) EA004872B1 (es)
ES (2) ES2435816T3 (es)
HK (1) HK1044277B (es)
HR (1) HRP20020090B1 (es)
HU (1) HU230660B1 (es)
IL (2) IL147641A0 (es)
MX (1) MXPA02001196A (es)
NO (1) NO321649B1 (es)
NZ (1) NZ516616A (es)
PL (1) PL199137B1 (es)
PT (1) PT1200090E (es)
SI (1) SI1200090T1 (es)
SK (1) SK287869B6 (es)
UA (1) UA72922C2 (es)
WO (2) WO2001008687A1 (es)
ZA (1) ZA200200823B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
AU4491200A (en) * 1999-08-03 2001-02-19 Lilly Icos Llc Beta-carboline pharmaceutical compositions
ES2278956T3 (es) 2001-04-25 2007-08-16 Lilly Icos Llc Derivados de carbolina como inhibidores de fosfodiesterasa 5 (pde5) para el tratamiento de enfermedades cardiovasculares y de la disfuncion erectil.
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2503290C (en) 2003-03-10 2012-12-04 Altana Pharma Ag Novel process for the preparation of roflumilast
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
ES2405787T3 (es) 2007-04-25 2013-06-03 Teva Pharmaceutical Industries Ltd. Formas de dosificación solidas
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
EP2042165A1 (de) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EP2400848A4 (en) 2009-02-26 2012-07-25 Thar Pharmaceuticals Inc CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
WO2011075801A1 (pt) 2009-12-21 2011-06-30 Acef S.A. Cubebina, lignana dibenzilbutirolactólica, seus derivados semi-sintéticos e sintéticos, bem como outras lignanas e neolignanas como agente vasodilatador na terapia da disfunção erétil
WO2012095151A1 (en) 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
EP2535049A1 (en) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil for the treatment of dementia
WO2014027981A2 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
WO2014027979A2 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet formulations comprising tadalafil and dapoxetine
US20150216798A1 (en) 2012-08-17 2015-08-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
US20150231092A1 (en) 2012-08-17 2015-08-20 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
CN105209025B (zh) 2013-04-11 2019-06-18 西梯茜生命工学股份有限公司 包括聚乙二醇类聚合物和/或乙烯基吡咯烷酮类聚合物作为分散稳定剂的含他达拉非游离碱的膜剂形式
EP3695841A3 (en) 2013-07-01 2020-11-04 The Research Foundation for the State University of New York Ship inhibition to combat obesity
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
US10702538B2 (en) 2014-06-17 2020-07-07 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells
WO2016001143A1 (en) 2014-06-30 2016-01-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Orally disintegrating formulations of tadalafil
EP2962684A1 (en) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of tadalafil
KR101648051B1 (ko) 2014-09-01 2016-08-12 주식회사 인트로팜텍 타다라필을 포함하는 휴대용 구강붕해정, 및 이의 제조방법
KR101538985B1 (ko) 2014-09-02 2015-07-24 주식회사 서울제약 타다라필 구강붕해필름 및 이의 제조방법
CN104758941A (zh) * 2015-04-27 2015-07-08 浙江永宁药业股份有限公司 一种利用羟丙基纤维素为粘合剂实现快速溶出的口服片剂
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
WO2017104862A1 (ko) * 2015-12-16 2017-06-22 동국제약 주식회사 타달라필 및 두타스테라이드를 포함하는 복합제제 조성물 및 그 제조방법
KR101716878B1 (ko) * 2016-05-12 2017-03-15 주식회사 유유제약 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
IT201700015145A1 (it) * 2017-02-10 2018-08-10 Altergon Sa Capsule di gelatina molle ad elevata stabilità
CN106821991A (zh) * 2017-03-21 2017-06-13 南京正科医药股份有限公司 一种微粒径他达拉非的制备方法
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
EP3731870A1 (en) 2017-12-26 2020-11-04 FTF Pharma Private Limited Liquid oral formulations for pde v inhibitors
HUE052118T2 (hu) 2018-01-10 2021-04-28 Gap S A Tadalafil szuszpenziót tartalmazó lágy zselatinkapszulák
US20210137919A1 (en) * 2018-02-07 2021-05-13 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
WO2023227185A1 (en) 2022-05-27 2023-11-30 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and nanomilling process for the preparation thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328929D0 (en) 1983-10-29 1983-11-30 Sterwin Ag Steroid compounds
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
JPH0818985B2 (ja) * 1989-05-30 1996-02-28 吉富製薬株式会社 溶出性の改良された製剤組成物
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
FR2710153B1 (fr) * 1993-09-17 1995-12-01 Alpha Mos Sa Procédés et appareils de détection des substances odorantes et applications.
EP1033128B2 (en) 1993-09-28 2011-11-23 R.P. Scherer GmbH Soft gelatin capsule manufacture
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
AU5049098A (en) * 1996-11-28 1998-06-22 Novo Nordisk A/S Pharmaceutical formulation
JP4292588B2 (ja) * 1997-01-31 2009-07-08 日産化学工業株式会社 ピリダジノン化合物類の経口製剤
ATE251139T1 (de) * 1997-07-11 2003-10-15 Janssen Pharmaceutica Nv (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
TR200001733T2 (tr) * 1997-12-16 2000-11-21 Pfizer Products Inc İktidarsızlığın tedavisi için etkili kombinasyon.
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
JP2000191518A (ja) * 1998-10-19 2000-07-11 Eisai Co Ltd 溶解性の改善された口腔内速崩壊性錠剤
CA2362918A1 (en) 1999-03-08 2000-09-14 Elizabeth Stoner Methods and compositions for treating erectile dysfunction
EP1173167A4 (en) * 1999-04-30 2004-07-14 Lilly Icos Llc TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
MXPA00003997A (es) * 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
UA71629C2 (en) * 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
AU4491200A (en) * 1999-08-03 2001-02-19 Lilly Icos Llc Beta-carboline pharmaceutical compositions

Also Published As

Publication number Publication date
HK1044277B (zh) 2014-02-28
ES2310166T3 (es) 2009-01-01
KR20060093355A (ko) 2006-08-24
AU4491200A (en) 2001-02-19
IL147641A (en) 2007-12-03
EP2338491A3 (en) 2011-11-30
ZA200200823B (en) 2003-04-30
EP1200091B1 (en) 2008-07-02
HUP0202513A3 (en) 2004-06-28
AU776722B2 (en) 2004-09-16
EP1200090B1 (en) 2013-09-11
US7182958B1 (en) 2007-02-27
PT1200090E (pt) 2013-11-25
NO321649B1 (no) 2006-06-19
CN1365282A (zh) 2002-08-21
EP1200091A1 (en) 2002-05-02
HRP20020090B1 (hr) 2014-03-28
HRP20020090A2 (en) 2003-12-31
CA2379948A1 (en) 2001-02-08
NZ516616A (en) 2003-07-25
EP2338491A2 (en) 2011-06-29
DE60039357D1 (de) 2008-08-14
AU4490900A (en) 2001-02-19
HU230660B1 (hu) 2017-06-28
KR20020014843A (ko) 2002-02-25
ES2435816T3 (es) 2013-12-23
IL147641A0 (en) 2002-08-14
KR100738861B1 (ko) 2007-07-16
NO20020532L (no) 2002-03-26
SK1732002A3 (en) 2002-05-09
HUP0202513A2 (en) 2002-10-28
DZ3179A1 (fr) 2001-02-08
ATE399554T1 (de) 2008-07-15
JP2010163464A (ja) 2010-07-29
US6841167B1 (en) 2005-01-11
PL199137B1 (pl) 2008-08-29
CA2379948C (en) 2008-03-25
UA72922C2 (uk) 2005-05-16
BR0012863A (pt) 2002-04-16
CZ2002386A3 (cs) 2002-07-17
CZ304624B6 (cs) 2014-08-13
PL353304A1 (en) 2003-11-03
EA200200118A1 (ru) 2002-06-27
MXPA02001196A (es) 2003-02-12
NO20020532D0 (no) 2002-02-01
EA004872B1 (ru) 2004-08-26
SI1200090T1 (sl) 2013-12-31
JP2003505509A (ja) 2003-02-12
EP1200090A1 (en) 2002-05-02
CN1213754C (zh) 2005-08-10
DK1200090T3 (da) 2013-11-25
WO2001008687A1 (en) 2001-02-08
WO2001008686A1 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
SK287869B6 (sk) Beta-carboline pharmaceutical compositions
KR20210147082A (ko) 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물
AU773666B2 (en) Beta-carboline drug products
CA2764172A1 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2014167579A2 (en) Stable pharmaceutical compositions of tadalafil
KR102598782B1 (ko) 알펠리십을 포함하는 제약 조성물
KR20090086128A (ko) 메만틴 약학 조성물
EP2364694A1 (en) Controlled-release formulations of pramipexole
TWI586379B (zh) 一種製作難溶藥物固體劑型的方法
CA3218977A1 (en) A plurality of tasquinimod particles and use thereof
KR20230024389A (ko) 우티델론의 고체 경구용 제제

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: ICOS CORPORATION, INDIANAPOLIS, IN, US

Free format text: FORMER OWNER: LILLY ICOS LLC, WILMINGTON, DE, US

Effective date: 20091214

MK4A Patent expired

Expiry date: 20200426